Literature DB >> 9256172

Cellular and molecular predictors of chronic renal dysfunction after initial ischemia/reperfusion injury of a single kidney.

H Azuma1, K Nadeau, M Takada, H S Mackenzie, N L Tilney.   

Abstract

BACKGROUND: Initial ischemia/reperfusion injury occurring secondary to organ retrieval, storage, and transplantation has been associated with late renal allograft deterioration and failure. In addition, there is an apparent synergy, reported in several clinical series, between the initial injuries of ischemia/reperfusion and acute rejection; the long-term results of graft survival are significantly deceased after both events in combination as compared with either alone or if no such episodes occur.
METHODS: In the present study, we examined patterns of proteinuria, cellular infiltration, cytokine expression, and glomerulosclerosis over time in Lewis and Fischer 344 rats after 45 min of warm ischemia of a single kidney and with or without contralateral nephrectomy. Both early (4 hr to 7 days) and late (2-52 weeks) events were studied serially in the affected kidneys morphologically, by immunohistology and by reverse transcriptase polymerase chain reaction.
RESULTS: Intercellular adhesion molecule 1, endothelin, and major histocompatibility complex class II expression were up-regulated within 2 to 5 days after injury; T cells and macrophages increased transiently. Proteinuria developed after approximately 8 weeks only in animals bearing a single injured kidney, and not in those with a retained native organ. Progressive morphological changes occurred after 16 weeks, including glomerulosclerosis, arterial obliteration, and interstitial fibrosis. After a period of relative quiescence, expression of intercellular adhesion molecule 1 again increased in relation to progressive macrophage infiltration and their associated products, particularly, interleukin 1, tumor necrosis factor-alpha, transforming growth factor-beta, and inducible nitric oxide synthase. Monocyte chemotactic protein 1 was intensely up-regulated by 24 weeks, coincident with a dramatic rise in this infiltrating population. These changes remained virtually at baseline in animals with a retained native kidney.
CONCLUSIONS: These data imply that chronic injury after significant initial ischemia and reperfusion occurs when there is already a 50% renal mass reduction, but not when two kidneys remain in place. Permanent nephron loss resulting from such an insult could account for this phenomenon. Early ischemia and reperfusion, if severe enough in a single kidney, may be an important antigen-independent risk factor for later renal deterioration and failure. In the context of a renal allograft, it may contribute to chronic rejection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9256172     DOI: 10.1097/00007890-199707270-00002

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  23 in total

Review 1.  Renal ischemia--reperfusion injury: an inescapable event affecting kidney transplantation outcome.

Authors:  R Böhmová; O Viklický
Journal:  Folia Microbiol (Praha)       Date:  2001       Impact factor: 2.099

2.  Kidney and recipient weight incompatibility reduces long-term graft survival.

Authors:  Magali Giral; Yohann Foucher; Georges Karam; Yann Labrune; Michelle Kessler; Bruno Hurault de Ligny; Mathias Büchler; François Bayle; Carole Meyer; Nathalie Trehet; Pascal Daguin; Karine Renaudin; Anne Moreau; Jean Paul Soulillou
Journal:  J Am Soc Nephrol       Date:  2010-05-20       Impact factor: 10.121

3.  Lack of long-term protective effect of antioxidant/anti-inflammatory therapy in transplant-induced ischemia/reperfusion injury.

Authors:  You-Lin Tain; Veronika Muller; Attila Szabo; Anna Dikalova; Kathy Griendling; Chris Baylis
Journal:  Am J Nephrol       Date:  2006-05-24       Impact factor: 3.754

Review 4.  Molecular pathways involved in loss of graft function in kidney transplant recipients.

Authors:  Valeria R Mas; Kellie J Archer; Mariano Scian; Daniel G Maluf
Journal:  Expert Rev Mol Diagn       Date:  2010-04       Impact factor: 5.225

5.  Neutralization of Gro alpha and macrophage inflammatory protein-2 attenuates renal ischemia/reperfusion injury.

Authors:  M Miura; X Fu; Q W Zhang; D G Remick; R L Fairchild
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

Review 6.  Acute kidney injury: a springboard for progression in chronic kidney disease.

Authors:  Manjeri A Venkatachalam; Karen A Griffin; Rongpei Lan; Hui Geng; Pothana Saikumar; Anil K Bidani
Journal:  Am J Physiol Renal Physiol       Date:  2010-03-03

7.  Progression of Chronic Kidney Disease After Acute Kidney Injury: Role of Self-Perpetuating Versus Hemodynamic-Induced Fibrosis.

Authors:  Maria Picken; Jianrui Long; Geoffrey A Williamson; Aaron J Polichnowski
Journal:  Hypertension       Date:  2016-08-22       Impact factor: 10.190

8.  Inhibition of COX 1 and 2 prior to renal ischemia/reperfusion injury decreases the development of fibrosis.

Authors:  Carla Q Feitoza; Giselle M Gonçalves; Patrícia Semedo; Marcos A Cenedeze; Hélady S Pinheiro; Felipe Caetano Beraldo; Oscar Fernando Pavão dos Santos; Vicente de Paula A Teixeira; Marlene A dos Reis; Marilda Mazzali; Alvaro Pacheco-Silva; Niels O S Câmara
Journal:  Mol Med       Date:  2008-08-18       Impact factor: 6.354

9.  Differential cellular immunolocalization of renal tumour necrosis factor-alpha production during ischaemia versus endotoxaemia.

Authors:  K K Donnahoo; X Meng; L Ao; A Ayala; B D Shames; M P Cain; A H Harken; D R Meldrum
Journal:  Immunology       Date:  2001-01       Impact factor: 7.397

10.  Inhibition of autoregulated TGFbeta signaling simultaneously enhances proliferation and differentiation of kidney epithelium and promotes repair following renal ischemia.

Authors:  Hui Geng; Rongpei Lan; Guichun Wang; Abdur R Siddiqi; Michael C Naski; Andrew I Brooks; Jeffrey L Barnes; Pothana Saikumar; Joel M Weinberg; Manjeri A Venkatachalam
Journal:  Am J Pathol       Date:  2009-04       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.